Merrimack Pharmaceuticals
MACK
#8887
Rank
A$0.32 B
Marketcap
A$21.65
Share price
0.00%
Change (1 day)
-4.83%
Change (1 year)

Earnings for Merrimack Pharmaceuticals (MACK)

Earnings in 2024 (TTM): -A$3.43 Million

According to Merrimack Pharmaceuticals's latest financial reports the company's current earnings are N/A. In 2023 the company made an earning of -A$3.12 Million a decrease over its 2022 earnings that were of -A$3.12 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Merrimack Pharmaceuticals from 2010 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -A$3.43 Million9.92%
2023 -A$3.12 Million0.09%
2022 -A$3.12 Million-16.9%
2021 -A$3.75 Million-49.89%
2020 -A$7.48 Million-75.39%
2019 -A$30.36 Million-68.58%
2018 -A$96.61 Million-19.4%
2017 -A$0.12 Billion-36.46%
2016 -A$0.19 Billion2.54%
2015 -A$0.19 Billion96.78%
2014 -A$93.5 Million-45.44%
2013 -A$0.18 Billion
2010 -A$66.46 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
A$10.24 B-317,067.24%๐Ÿ‡ซ๐Ÿ‡ท France
Geron
GERN
-A$53.5 Million 1,554.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Clovis Oncology
CLVS
-A$0.32 Billion 9,523.90%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-A$41.56 Million 1,185.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Eterna Therapeutics
ERNA
-A$23.65 Million 631.30%๐Ÿ‡บ๐Ÿ‡ธ USA